Chordia Therapeutics Inc. (TYO:190A)

Chordia Therapeutics Income Statement

Financials in millions JPY. Fiscal year is September - August.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Nov 30, 2025	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023
Revenue	-	-	-	2,500
Gross Profit	-	-	-	2,500
Selling, General & Admin	339.1	364.47	301.6	291.12
Research & Development	1,133	1,425	1,500	1,997
Operating Expenses	1,472	1,790	1,801	2,288
Operating Income	-1,472	-1,790	-1,801	212.06
Currency Exchange Gain (Loss)	-6.6	-3.9	-3.6	-12.24
Other Non Operating Income (Expenses)	15.78	10.23	-19.71	25.95
Pretax Income	-1,462	-1,783	-1,825	225.76
Income Tax Expense	2.29	2.42	2.42	2.42
Net Income	-1,465	-1,786	-1,827	223.34
Net Income to Common	-1,465	-1,786	-1,827	223.34
Shares Outstanding (Basic)	69	69	59	56
Shares Outstanding (Diluted)	69	69	59	56
Shares Change (YoY)	12.02%	16.82%	4.05%	-
EPS (Basic)	-21.22	-26.03	-31.11	3.96
EPS (Diluted)	-21.22	-26.03	-31.11	3.96
Free Cash Flow	-	-1,842	-1,938	543.38
Free Cash Flow Per Share	-	-26.85	-32.99	9.63
Gross Margin	-	-	-	100.00%
Operating Margin	-	-	-	8.48%
Profit Margin	-	-	-	8.93%
Free Cash Flow Margin	-	-	-	21.73%
EBITDA	-1,469	-1,787	-1,797	218.1
EBITDA Margin	-	-	-	8.72%
D&A For EBITDA	2.35	2.7	4.09	6.04
EBIT	-1,472	-1,790	-1,801	212.06
EBIT Margin	-	-	-	8.48%
Effective Tax Rate	-	-	-	1.07%

Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.